Table 3.
PFS and OS analyses adjusted for age, sex, and treatment type
| Characteristic | HR for PFS (95% CI) | p-value | HR for OS (95% CI) | p-value |
|---|---|---|---|---|
|
| ||||
| Race | ||||
| Asian (vs Non-Asian) | 0.78 (0.44–1.37) | 0.38 | 0.64 (0.34–1.21) | 0.15 |
|
| ||||
| Race | ||||
| White/Black (vs Other races) | 1.49 (0.93–2.38) | 0.09 | 1.55 (0.92–2.60) | 0.09 |
|
| ||||
| Stage | ||||
| Early (vs Advanced) | 0.59 (0.37–0.92) | 0.02 | 0.45 (0.28–0.73) | 0.002 |
|
| ||||
| Chemo Regimen | ||||
| CHOP/Anthracycline (vs Non-Anthracycline) | 1.06 (0.53–2.12) | 0.87 | 0.79 (0.39–1.61) | 0.52 |
|
| ||||
| Treatment Category | ||||
| Stage 1 and 2 Patients | ||||
| Chemotherapy alone | 1.00 | 1.00 | ||
| Radiation alone | 0.21 (0.07–0.65) | 0.01 | 0.30 (0.08–0.43) | 0.06 |
| Combined modality Therapy | 0.24 (0.12–0.51) | 0.0001 | 0.33 (0.14–0.78) | 0.01 |
|
| ||||
| BMT status | ||||
| Only CR patients | ||||
| Transplant in CR1 (vs No Transplant) | 0.59 (0.22–1.58) | 0.27 | 0.67 (0.19–2.42) | 0.53 |
Abbreviations: HR, hazard ratio; CI, confidence interval; PFS, progression free survival; OS, overall survival; CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; BMT, bone marrow transplantation; CR1, first complete remission.